Mankind Pharma (MANKIND) Panoramica del titolo
Mankind Pharma Limited sviluppa, produce e commercializza formulazioni farmaceutiche e prodotti sanitari di consumo principalmente in India e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per MANKIND dai nostri controlli di rischio.
MANKIND Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Mankind Pharma Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹2,532.00 |
| Massimo di 52 settimane | ₹2,716.50 |
| Minimo di 52 settimane | ₹1,909.70 |
| Beta | 0.45 |
| Variazione di 1 mese | 5.90% |
| Variazione a 3 mesi | 21.79% |
| Variazione di 1 anno | -0.47% |
| Variazione a 3 anni | 39.10% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | 78.02% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 29
MANKIND: Higher Growth Assumptions Will Be Offset By Weaker Profitability
Analysts have lifted their fair value estimate for Mankind Pharma from ₹1,990 to about ₹2,062, reflecting updated assumptions that combine higher revenue growth expectations with slightly lower profit margin forecasts and a modestly reduced future P/E multiple. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider several corporate actions.
Aggiornamento della narrazione • Jun 15
MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating
Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.
Aggiornamento della narrazione • Jun 01
MANKIND: Higher Future Multiple And Subsidiary Exit Will Support Further Upside
Analysts have raised their fair value estimate for Mankind Pharma from ₹2,515.74 to ₹2,653.40, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, at 15:10 IST to consider standalone and consolidated audited financial results for the quarter and year ended March 31, 2026; review security cover for existing non convertible debentures after the redemption of ₹1,250 crore of NCDs on April 16, 2026; consider management changes; and evaluate an additional investment in its subsidiary, Mankind Medicare Private Limited (source: company board agenda).Articolo di analisi • May 22
Analysts Have Made A Financial Statement On Mankind Pharma Limited's (NSE:MANKIND) Yearly Report
It's been a good week for Mankind Pharma Limited ( NSE:MANKIND ) shareholders, because the company has just released...Recent updates
Aggiornamento della narrazione • Jun 29
MANKIND: Higher Growth Assumptions Will Be Offset By Weaker Profitability
Analysts have lifted their fair value estimate for Mankind Pharma from ₹1,990 to about ₹2,062, reflecting updated assumptions that combine higher revenue growth expectations with slightly lower profit margin forecasts and a modestly reduced future P/E multiple. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider several corporate actions.Aggiornamento della narrazione • Jun 15
MANKIND: Subsidiary Reshuffle And Higher P/E Assumptions Will Support Re Rating
Analysts have raised the price target for Mankind Pharma slightly to ₹3,100 from ₹3,085.68, reflecting updated assumptions regarding a higher future P/E multiple, as well as adjusted expectations for revenue growth, profit margins, and the discount rate. What's in the News Board meeting on May 19, 2026 to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, consider realignment of security cover for existing non convertible debentures after redemption of ₹12,50,00,00,000 of NCDs on April 16, 2026, review management changes, and evaluate additional investment in subsidiaries.Aggiornamento della narrazione • Jun 01
MANKIND: Higher Future Multiple And Subsidiary Exit Will Support Further Upside
Analysts have raised their fair value estimate for Mankind Pharma from ₹2,515.74 to ₹2,653.40, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on May 19, 2026, at 15:10 IST to consider standalone and consolidated audited financial results for the quarter and year ended March 31, 2026; review security cover for existing non convertible debentures after the redemption of ₹1,250 crore of NCDs on April 16, 2026; consider management changes; and evaluate an additional investment in its subsidiary, Mankind Medicare Private Limited (source: company board agenda).Articolo di analisi • May 22
Analysts Have Made A Financial Statement On Mankind Pharma Limited's (NSE:MANKIND) Yearly Report
It's been a good week for Mankind Pharma Limited ( NSE:MANKIND ) shareholders, because the company has just released...Aggiornamento della narrazione • May 05
MANKIND: Subsidiary Exit And Firm Margins Will Support Further Upside
Mankind Pharma's analyst price target has been adjusted slightly higher from ₹2,506.53 to ₹2,515.74 as analysts update their assumptions around revenue growth, profit margin and forward P/E expectations. What's in the News The board is scheduled to meet on April 13, 2026, at 15:00 Indian Standard Time to review corporate matters, including the subsidiary structure (company filing).Aggiornamento della narrazione • Apr 20
MANKIND: Subsidiary Closure Decision Will Support Future Re Rating Potential
Analysts have made a slight trim to the price target for Mankind Pharma, with fair value moving from ₹3,100.00 to about ₹3,085.68 as they refresh assumptions around revenue growth, profit margins, and future P/E levels. What's in the News The board plans to meet on Apr 13, 2026, at 15:00 Indian Standard Time to review and approve the closure of Mankind Pharma Lanka Private Limited, the wholly owned subsidiary in Sri Lanka, following changes in local regulatory requirements (Key Developments).Aggiornamento della narrazione • Apr 06
MANKIND: Upcoming Results And Solid Margins Will Support Further Upside
Analysts have cut their price target on Mankind Pharma by ₹30 to reflect slightly lower assumptions for revenue growth, profit margins and future P/E multiples, resulting in a modest reset in fair value expectations. What's in the News A board meeting is scheduled on Feb 3, 2026 at 15:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).Aggiornamento della narrazione • Mar 22
MANKIND: Upcoming Board Review And Steady Assumptions Will Support Bullish Re Rating
Analysts have kept Mankind Pharma's fair value estimate unchanged at ₹3,100 per share, citing slightly higher assumptions for revenue growth at 14.04% and profit margin at 21.31%, along with a marginally lower future P/E of 41.44x. What's in the News Board meeting scheduled for Feb 03, 2026 at 15:00 IST to review and approve unaudited standalone financial results for the quarter ended Dec 31, 2025, along with the Limited Review Report (company filing).Aggiornamento della narrazione • Mar 08
MANKIND: Upcoming Results And Firmer Margins Will Support Bullish Re-Rating
Analysts have slightly reduced their fair value estimate for Mankind Pharma to ₹3,100 from ₹3,110, reflecting updated assumptions around modestly different revenue growth, margins, and future P/E expectations. What's in the News A board meeting is scheduled on February 3, 2026, at 15:00 Indian Standard Time to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, along with the Limited Review Report (Key Developments).Aggiornamento della narrazione • Feb 22
MANKIND: Upcoming Results Will Support Further Upside Despite Modest Assumption Cuts
Analysts have trimmed their price target for Mankind Pharma from about ₹2,631 to about ₹2,537. This reflects slightly lower assumptions for revenue growth, profit margins and future P/E multiples, alongside a modestly reduced discount rate.Aggiornamento della narrazione • Feb 08
MANKIND: Fair Value Outlook Will Reflect Lower Growth And Higher Margins
Analysts have trimmed their fair value estimate for Mankind Pharma from ₹2,150 to ₹1,990, citing updates to revenue growth, profit margin and assumed future P/E levels in their revised models. What's in the News Mankind Pharma has scheduled a board meeting on Feb 03, 2026, at 15:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025, along with the Limited Review Report (Key Developments).Aggiornamento della narrazione • Jan 24
MANKIND: Firmer Margins And Upcoming Results Will Support Future Bullish Re-Rating
Analysts have trimmed their fair value estimate for Mankind Pharma from ₹3,260 to ₹3,110, citing slightly softer revenue growth expectations, partly offset by firmer profit margin and P/E assumptions. What's in the News Board meeting scheduled on Feb 03, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Aggiornamento della narrazione • Jan 10
MANKIND: Rising Margins And Upcoming Results Will Support Further Upside
Analysts have trimmed their price target for Mankind Pharma from ₹2,699 to ₹2,631, citing updated assumptions that reflect slightly different expectations for revenue growth, profit margins and future P/E multiples. What's in the News Mankind Pharma has scheduled a board meeting on Nov 06, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Articolo di analisi • Dec 14
Does Mankind Pharma (NSE:MANKIND) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Aggiornamento della narrazione • Dec 14
MANKIND: Strong Profitability Outlook Will Support Future Bullish Re-Rating
Narrative Update Analysts have modestly trimmed their fair value estimate for Mankind Pharma to ₹3,260 from ₹3,300, reflecting slightly lower expected revenue growth and valuation multiples, partly offset by an improved profit margin outlook. What's in the News Board meeting scheduled for November 6, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) Valuation Changes Fair Value Estimate reduced slightly to ₹3,260 from ₹3,300, reflecting a modest downward revision in intrinsic value.Aggiornamento della narrazione • Nov 27
MANKIND: Rising Margins And Upcoming Results Will Drive Further Upside
Analysts have slightly reduced their fair value estimate for Mankind Pharma from ₹2,725.59 to ₹2,699.12. They cite minor adjustments in projected revenue growth and profit margins as influencing factors.Articolo di analisi • Nov 09
Analysts Are Updating Their Mankind Pharma Limited (NSE:MANKIND) Estimates After Its Second-Quarter Results
Last week, you might have seen that Mankind Pharma Limited ( NSE:MANKIND ) released its quarterly result to the market...Aggiornamento della narrazione • Nov 08
MANKIND: Expansion Into Russia And Rising Margins Will Drive Upside
Analysts have revised the fair value estimate for Mankind Pharma down from ₹2,799.65 to ₹2,725.59. This revision reflects slightly lower revenue growth expectations, partially offset by stronger profit margins and a marginally higher discount rate.Articolo di analisi • Nov 08
Mankind Pharma Limited's (NSE:MANKIND) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 53.4x Mankind Pharma Limited ( NSE:MANKIND ) may be sending very bearish...Aggiornamento della narrazione • Sep 05
Chronic Therapy Demand And E-Commerce Will Fuel Future Expansion
With little change in both net profit margin and future P/E, there has been no effective revision to Mankind Pharma's consensus analyst price target, which remains at ₹2800. What's in the News Incorporated wholly owned subsidiary in Russia under the name Mankind Pharma LLC.Articolo di analisi • Aug 03
Mankind Pharma Limited (NSE:MANKIND) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
The quarterly results for Mankind Pharma Limited ( NSE:MANKIND ) were released last week, making it a good time to...Articolo di analisi • Jul 23
We Think You Should Be Aware Of Some Concerning Factors In Mankind Pharma's (NSE:MANKIND) Earnings
Mankind Pharma Limited's ( NSE:MANKIND ) robust recent earnings didn't do much to move the stock. We believe that...
Nuova narrazione • Nov 12
Decisive Acquisition And Global Expansion Set To Revitalize Revenue Growth And Profitability
Strategic acquisitions and specialization in high-entry barrier segments are expected to enhance revenue growth and margins through synergies and R&D leverage.Rendimenti per gli azionisti
| MANKIND | IN Pharmaceuticals | IN Mercato | |
|---|---|---|---|
| 7D | 1.8% | 0.9% | -1.1% |
| 1Y | -0.5% | 12.6% | -3.2% |
Ritorno vs Industria: MANKIND ha avuto una performance inferiore rispetto al Indian Pharmaceuticals che ha registrato un rendimento 12.6 % nell'ultimo anno.
Rendimento vs Mercato: MANKIND ha superato il mercato Indian che ha restituito -3.2 % nell'ultimo anno.
Volatilità dei prezzi
| MANKIND volatility | |
|---|---|
| MANKIND Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 3.9% |
Prezzo delle azioni stabile: MANKIND non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di MANKIND è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1991 | 19,620 | Sheetal Arora | www.mankindpharma.com |
Mankind Pharma Limited sviluppa, produce e commercializza formulazioni farmaceutiche e prodotti sanitari di consumo principalmente in India e a livello internazionale. L'azienda sviluppa prodotti farmaceutici per terapie acute e croniche nei settori degli antinfettivi, cardiovascolare, gastrointestinale, antidiabetico, dermatologico, del dolore/analgesico, neuro/CNS, delle vitamine/minerali/nutrienti e delle malattie respiratorie. Fornisce prodotti sanitari di largo consumo, come preservativi, kit per il rilevamento della gravidanza, contraccettivi d'emergenza, polveri antiacide, integratori vitaminici e minerali e preparati antiacne.
Mankind Pharma Limited Riepilogo dei fondamenti
| MANKIND statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹1.03t |
| Utili (TTM) | ₹19.13b |
| Ricavi(TTM) | ₹142.78b |
54.7x
Rapporto P/E7.3x
Rapporto P/SMANKIND è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MANKIND Conto economico (TTM) | |
|---|---|
| Ricavi | ₹142.78b |
| Costo del fatturato | ₹40.52b |
| Profitto lordo | ₹102.26b |
| Altre spese | ₹83.13b |
| Utili | ₹19.13b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 46.32 |
| Margine lordo | 71.62% |
| Margine di profitto netto | 13.40% |
| Rapporto debito/patrimonio netto | 37.5% |
Come si è comportato MANKIND nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.08%
Rendimento attuale del dividendon/a
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/09 11:41 |
| Prezzo dell'azione a fine giornata | 2026/07/09 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Mankind Pharma Limited è coperta da 36 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Ashwin Mehta | Ambit Capital |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |